TrialCancer science2017

Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study.

Mototsugu Oya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.